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Introduction
William Heberden in 1806 was probably the first to
suggest “some degree of heredity” for rheumatoid arthritis
(RA). Subsequent twin- and family-based studies have
shown that both genetic and environmental factors influ-
ence susceptibility to RA, leading to its description as a
complex or multifactorial condition. There have been many
attempts to elucidate both the genetic and environmental
components, but the aetiology remains largely unclear. In
common with many other autoimmune chronic inflamma-
tory conditions, associations with genes of the human leu-
cocyte antigen (HLA) complex have been described. The
original observation by Stastny in 1978 [1] of an associa-
tion with the HLA DRB1 locus in 80 patients has become
one of the few examples of a consistently associated gene
in RA. Estimates suggest that the HLA locus probably
accounts for no more than a third of the total genetic
component of susceptibility [2], leaving the majority still 
to be determined. This review considers some of the
approaches currently available for the investigation of the
non-HLA genetic basis of susceptibility to RA.
Linkage analysis
Complex diseases do not lend themselves to parametric
linkage analysis, as this technique depends on following
the inheritance of genetic markers in extended pedigrees
to look for cosegregation of marker alleles in affected indi-
viduals, under a defined model of inheritance. RA clearly
does not follow Mendelian inheritance patterns, and large,
extended pedigrees are difficult or impossible to ascertain.
Thus, until recently, the search for RA disease genes was
targeted to potential candidate genes tested in disease-
association studies.
Affected-sibling-pair methods
Nonparametric (model-free) linkage analysis can be
carried out on small, nuclear families, such as affected
sibling pairs (ASPs), provided sufficient families can be
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collected. Technological developments in the early 1990s
making possible high-throughput genotyping of informa-
tive markers (microsatellites; simple repetitive DNA
sequences, highly polymorphic between individuals in
terms of the number of repeats) combined with the collec-
tion of large numbers of small nuclear families led to
groups in Europe [2], Japan [3], the USA [4], and the UK
(Worthington J, unpublished data) to embark upon whole-
genome screens in search of RA disease genes. This
exciting approach of systematically scanning the genome
for regions containing disease loci provides the opportu-
nity to identify previously undescribed genes that would
never be found by the candidate-gene approach.
The results published to date all represent the first stage of
genome screens, in which many potential loci have been
identified, but as yet, with the exception of DRB1, none has
reached the level of statistical significance (P <2.2×10 –5)
recommended for such approaches [5]. As a result, many
of these loci will turn out to be false positives, and only
replication studies in independent cohorts will determine
the true regions of linkage. Further, the individual studies
published so far are limited by a lack of power to exclude
regions or to detect loci with modest effects – the likely
scenario in RA – and this may require the use of as many
as 2000 ASPs [6]. All groups are collecting more families,
and plans are already in place to carry out meta-analysis of
the data, which may prove to be the most effective way to
achieve the necessary power, if the differences between
the cohorts are taken into account. We must expect, then,
to wait some time before whole-genome screens in RA
accurately direct us to disease loci.
On a more encouraging note, even in the initial publica-
tions, a number of promising loci have been detected in
more than one study. This is perhaps particularly surpris-
ing in view of the relative lack of concordance between
whole-genome screens reported for some other condi-
tions (e.g. multiple sclerosis, schizophrenia). This lack of
agreement has, unfortunately, led to some scepticism
about whole-genome screens but actually does not
suggest an inherent flaw in the approach: it is more likely a
reflection of heterogeneity between the cohorts studied.
The possibility of both phenotypic and genetic hetero-
geneity in complex diseases is a potential difficulty that
must be taken into account when attempting to define the
genetic basis of a complex disease, whether using
linkage- or nonlinkage-based approaches.
Establishing evidence of linkage using ASP methods is
just the first step, and one of the greatest challenges to
molecular genetics is to identify a disease gene from a
region of linkage. The size of an initial linkage region may
be many tens of centimorgans, and recent publications
have shown that chance variation in the location estimate
is substantial [7,8], suggesting that it may be necessary to
follow up a large area on either side of the linkage peak.
Experience so far suggests that even with fine mapping
using a dense marker map, it has not been possible to
narrow down regions to less than 10cM in any complex
disease. As regions of this size may contain hundreds of
genes, it is vital to define a smaller region by linkage-
disequilibrium mapping before moving on to target genes.
Linkage-disequilibrium analysis and
association studies
Family-based association tests
A large area of linkage may be narrowed down by using
methods that detect association in the presence of
linkage. As association between a marker and a disease
locus depends upon the presence of linkage disequilib-
rium, in an outbred population, association can be
detected only over a small distance, typically less than
1cM. A number of family-based association methods have
been proposed, the most commonly used being the trans-
mission disequilibrium test (TDT) [9].
The test examines the transmission of potential disease
alleles from a parent who is heterozygous for the marker to
an affected offspring. It is a test of association only in the
presence of linkage, and because family members act as
controls, spurious associations due to population differ-
ences do not arise. The original test uses a single affected
offspring and both parents. A number of extensions to the
original TDT have been proposed that allow both parents
and unaffected sibling to be analysed, making maximum
use of incomplete nuclear family data. It is now also possi-
ble to analyse dichotomous and quantitative variables (e.g.
age at onset) and to include covariates (e.g. exposure to
smoking) in the analysis. An extensive list of available
methods and software can be found at the Genetic analy-
sis web page at Rockefeller University (http://linkage.rock-
efeller.edu/).
Tests are available for both single-nucleotide polymor-
phisms (SNPs) and multiallelic markers such as
microsatellites. As the TDT is dependent upon the number
of informative transmissions, microsatellite markers are
often more useful. If 100 parents are genotyped, 80 infor-
mative transmissions will be expected for a microsatellite
marker with 80% heterozygosity, whereas the maximum
heterozygosity measure for a SNP is only 50%. However,
at least two multilocus haplotype methods have been
developed for the TDT, which should overcome the low
information content of single SNPs by combining up to
four SNPs in a single haplotype.
At present, there are few published studies in RA using
TDT methods. Recent papers have looked at regions of
linkage and used the TDT to test for association, leading
to more significant results than were observed using
linkage [10,11]. The TDT has become a very versatileArthritis Research    Vol 3 No 4 John and Worthington
methodology, allowing a range of family structures, marker
types, and phenotype data to be analysed simultaneously.
This versatility, coupled with the increased power of an
association-based method, will inevitably lead to increased
use of the TDT in the search for RA susceptibility genes.
Case–control studies
Linkage studies are resource intensive and dependent
on the availability of large family collections. It is there-
fore not surprising that many investigators have chosen
to target candidate genes directly. These studies are
usually association based, using case–control cohorts. A
number of polymorphisms in genes thought to be
involved in RA pathology have been investigated, but
results have often been conflicting. An example is the
interleukin(IL)-1 gene cluster, containing IL-1B, IL-1A,
and the IL-1-receptor antagonist. A number of studies
[e.g. 12] have suggested that polymorphisms in this
gene cluster are associated with RA, whereas others
have shown no association [e.g. 13]. This apparent
inconsistency may be explained by a number of factors,
including clinical heterogeneity (associations are often
only shown with certain subsets of disease), genetic het-
erogeneity (it should not be unexpected to find ethnic
differences in associations), and study design (small,
underpowered sample sizes, poor quality control of
genotyping data, and inappropriate selection of controls
will all contribute to inconsistent findings).
Despite the potential difficulties, association studies have
the significant advantage over linkage studies of having
greater power to detect small effects. For example, only
123 affected individuals in a case–control study would be
required to detect a genetic relative risk of 2 for a disease
allele with a frequency of 10% with 80% power, at
P=0.05 [6]. Although the genetic relative risk associated
with an unknown disease gene cannot be established
accurately, there is much evidence that no disease gene in
RA will have an effect greater than HLA and that some RA
genes may well have a genetic relative risk no greater than
twofold. In addition to offering increased power, the move
towards genotyping SNPs rather than microsatellites
means that case–control studies are more efficient.
Even when reasonable sample sizes are used, applying a
significance level of P=0.05 will still lead to 1 in 20
results being false positives. In order to minimize type 1
error, it would be desirable to design studies with suffi-
cient power to detect an effect at a level of significance
corrected for the number of markers or genes to be
tested. The obvious drawback of this rigorous approach
is that this sort of correction for multiple tests will result in
unrealistic sample sizes. For this reason, it is perhaps
more appropriate to accept a P value of < 0.05 in an
initial study and to replicate the result in an independent
data set [14].
The selection of appropriately matched controls has also
been the subject of discussion within the community of
geneticists. Ethnically unmatched controls may lead to pos-
itive results due to population stratification. If two popula-
tions have subtle genetic differences and the cases come
predominantly from one population, positive associations
will be observed but the true association will be with the
population rather than the disease. In reality, the extent of
this problem is unclear, because false-positive results
occur for many reasons. The problem has recently been
addressed by Pritchard and Rosenberg [15], who propose
using a panel of unassociated markers to test for popula-
tion stratification within the cohort under investigation.
Future considerations
The rapid pace of developments in molecular genetics and
molecular medicine make it almost impossible to accu-
rately predict more than a couple of years into the future. It
seems likely that our investigation of RA genetics will con-
tinue, in the immediate future, to be based on a combina-
tion of linkage and association studies, with refinements to
improve the power and sensitivity. Linkage mapping of
ASP collections will probably use a higher density of
markers, and information derived from other sources such
as animal models may be used to target the linkage
studies. The investigation of loci homologous to regions
mapped in rodent models of disease has proved fruitful in
a number of diseases, including arthritis [16]. With the
human genome now sequenced and the mouse sequence
expected within the year, the accurate targeting of homol-
gous regions for linkage analysis will be greatly facilitated.
The ASP collections may also become the samples of
choice for association-based studies. Case–control and
TDT methods have routinely used sporadic cases, but in a
complex disease such as RA, any study design based on
sporadic cases may be selecting more for environmental
than for genetic factors. Risch [17] has advocated the use
of ASPs in an association study design with unrelated
controls as the most powerful approach to detect disease
genes. For example, using 102 ASPs (408 individuals in
total) has an 80% power to detect a genetic relative risk of
2 (for the heterozygote) for a disease allele of 20% fre-
quency with a significance level of P=5×10 –8. Intuitively,
taking cases with a family history should increase the
chances of detecting a genetic effect. A recent publication
demonstrated an association to the tumour necrosis factor
receptor II in two independent data sets in which the case
had a family history of disease (defined as at least one
affected first-degree relative) [18]. This association was
not observed in a cohort of sporadic cases.
So far, association studies in RA have concentrated on a
few, well established candidate genes. In theory, it is possi-
ble to search the whole genome by association methods.
The likelihood of success using this approach dependsAvailable online http://arthritis-research.com/content/3/4/216
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upon the number of markers typed and the extent of
linkage disequilibrium that exists between markers. It is
beyond the scope of this review to discuss whole-genome
linkage-disequilibrium mapping and whether it will be
applied to RA. More thorough discussion of the feasibility
of this approach has recently been published [17,19].
With the completion of the human genome sequence, all
transcribed genes should soon be identified. Additional
information about tissue expression and functional domains
will allow us to make much more educated decisions about
which genes to target. With initiatives such as the SNP
consortium releasing >300,000 SNPs into the public
domain, it will soon be possible to select SNPs in candi-
date genes from a list of all transcribed genes in the
genome. This more focused approach may lead to greater
success in detecting disease genes, because testing
potentially functional SNPs within genes for association
decreases the dependence upon linkage disequilibrium.
However, even for a single gene, there is no clear consen-
sus about how many SNPs one might need to analyse. A
recent publication examining SNPs around the APOE
locus failed to find an association with the majority of the
common SNPs within a 1.5-Mb region of the gene [20].
Case–control studies have most commonly been used to
look at single markers; analysing several markers within a
gene or small region has been more problematic, because
it is difficult to determine haplotypes in the absence of
family information. There is now a concentrated effort to
evaluate methods of haplotyping unrelated individuals, and
a recent publication successfully identified the APOE locus
using haplotyping methods [21]. Drysdale et al used haplo-
types in the b2-adrenergic receptor to detect association
with drug responsiveness; they suggested that haplotypes
were more successful in detecting associations than in
analysing individual SNPs [22].
Conclusion
Having reached the landmark event of sequencing the
human genome, perhaps we are now in a position to really
begin dissecting the aetiology of RA. Ultimately, this will
be achieved only by using a combination of the techniques
described in this review, together with high-quality pheno-
typic and epidemiological data. This will also require the
development of methods of analysis based on more
sophisticated models of complex disease which allow for
gene–gene and gene–environment interactions.
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